Ismael Riquelme

Dr. Ismael Riquelme

Universidad Autónoma de Chile, Chile
orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2014 in Virchows Archiv
Verified
Journal Article
Closed access
PDF file
OTOscar Tapia
Oscar Tapia
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
PLPamela Leal
Pamela Leal
ASAlejandra Sandoval
Alejandra Sandoval
SASusana Aedo
Susana Aedo
Juan Carlos RoaJuan Carlos Roa
Juan Carlos Roa

12 October 2015 in Cellular Oncology
Verified
Journal Article
Closed access
PDF file
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
OTOscar Tapia
Oscar Tapia
PLPamela Leal
Pamela Leal
ASAlejandra Sandoval
Alejandra Sandoval
MVMatthew Varga
Matthew Varga
Juan Carlos RoaJuan Carlos Roa
Juan Carlos Roa

22 July 2015 in Oncotarget
Verified
Journal Article
Open access
PDF file
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
KSKathleen Saavedra
Kathleen Saavedra
JEJaime A. Espinoza
Jaime A. Espinoza
HWHelga Weber
Helga Weber
PGPatricia García
Patricia García
CBCarolina Bizama
Carolina Bizama
Molecular classification of gastric cancer: Towards a pathway-driven targeted therapy

Verified
Journal Article
Open access
PDF file
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
PLPablo Letelier
Pablo Letelier
ARAngela L. Riffo-Campos
Angela L. Riffo-Campos
PBPriscilla Brebi
Priscilla Brebi
Juan Carlos RoaJuan Carlos Roa
Juan Carlos Roa
Gastric cancer is the third leading cause of cancer mortality worldwide. Unfortunately, most gastric cancer cases are diagnosed in an advanced, non-curable stage and with a limited response to chemotherapy. Drug resistance is one of the most important causes of therapy failure in gastric cancer patients. Although the mechanisms of drug resistance have been broadly studied, the regulation of these mechanisms has not been completely understood. Accumulating evidence has recently highlighted the role of microRNAs in the development and maintenance of drug resistance due to their regulatory features in specific genes involved in the chemoresistant phenotype of malignancies, including gastric cancer. This review summarizes the current knowledge about the miRNAs’ characteristics, their regulation of the genes involved in chemoresistance and their potential as targeted therapies for personalized treatment in resistant gastric cancer.

Verified
Journal Article
Open access
PDF file
PPPablo Perez-Moreno
Pablo Perez-Moreno
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
PGPatricia Garcia
Patricia Garcia
PBPriscilla Brebi
Priscilla Brebi
Juan Carlos RoaJuan Carlos Roa
Juan Carlos Roa
Gallbladder cancer (GBC) is an aggressive neoplasm that in an early stage is generally asymptomatic and, in most cases, is diagnosed in advanced stages with a very low life expectancy because there is no curative treatment. Therefore, understanding the early carcinogenic mechanisms of this pathology is crucial to proposing preventive strategies for this cancer. The main risk factor is the presence of gallstones, which are associated with some environmental factors such as a sedentary lifestyle and a high-fat diet. Other risk factors such as autoimmune disorders and bacterial, parasitic and fungal infections have also been described. All these factors can generate a long-term inflammatory state characterized by the persistent activation of the immune system, the frequent release of pro-inflammatory cytokines, and the constant production of reactive oxygen species that result in a chronic damage/repair cycle, subsequently inducing the loss of the normal architecture of the gallbladder mucosa that leads to the development of GBC. This review addresses how the different risk factors could promote a chronic inflammatory state essential to the development of gallbladder carcinogenesis, which will make it possible to define some strategies such as anti-inflammatory drugs or public health proposals in the prevention of GBC.

28 April 2020 in Marine Drugs
Verified
Journal Article
Open access
PDF file
MRMaría Elena Reyes
María Elena Reyes
Ismael RiquelmeIsmael Riquelme
Ismael Riquelme
TSTomás Salvo
Tomás Salvo
Louise ZanellaLouise Zanella
Louise Zanella
PLPablo Letelier
Pablo Letelier
PBPriscilla Brebi
Priscilla Brebi
Fucoidans are sulphated polysaccharides that can be obtained from brown seaweed and marine invertebrates. They have anti-cancer properties, through their targeting of several signaling pathways and molecular mechanisms within malignant cells. This review describes the chemical structure diversity of fucoidans and their similarity with other molecules such as glycosaminoglycan, which enable them to participation in diverse biological processes. Furthermore, this review summarizes their influence on the development of metastasis and drug resistance, which are the main obstacles to cure cancer. Finally, this article discusses how fucoidans have been used in clinical trials to evaluate their potential synergy with other anti-cancer therapies.